Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 678 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mild Alzheimer's Disease Clear all
Terminated Phase 3 Interventional Results available

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

NCT01900665
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 90 Years
Enrollment
2,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
120
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

NCT02079909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T-817MA-H, T-817MA-L, Placebo
Drug
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Industry
Eligibility
55 Years to 85 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Platform-based Mild Cognitive Impairment (MCI) Trial

NCT03987464
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Planning for the Future, Enhanced Medical Engagement, Confidence Building and Social Engagement, Physical Intervention, Medical Adherence
Behavioral
Lead sponsor
Allison Gibson
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 8, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional Results available

2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

NCT02916056
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Azeliragon 5mg
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
65
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

NCT01230853
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

NCT02045056
View directory record Official record
Conditions
Preclinical Alzheimer's Disease
Interventions
Gemfibrozil, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 8, 2026, 7:14 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

ScentAware and OCT in MCI vs HC

NCT06377241
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
ScentAware, UPSIT
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00454870
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MEM 3454
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Phoenix, Arizona • Glendale, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment

NCT04206670
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 8, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease

NCT00299988
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Intravenous Immunoglobulin, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

NCT00329082
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2062430, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2009 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease

NCT05138848
View directory record Official record
Conditions
Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change, Amyloid
Interventions
Time in Bed Restriction, Sleep Schedule
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Not applicable Interventional Results available

STIM+: PET Biomarker Education & Disclosure

NCT04818255
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
Interventions
PET Biomarker Disclosure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 8, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

NCT01255163
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT04602624
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Redlands, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 8, 2026, 7:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

NCT06223360
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 89 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

NCT00742417
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albutein 5%, Control
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Whiting, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00348140
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
49
States / cities
Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

NCT02624778
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3002813, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 8, 2026, 7:14 AM EDT
Withdrawn Phase 2 Interventional

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

NCT02707978
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 8, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study

NCT02726906
View directory record Official record
Conditions
Aging, Cognitive Ability, General
Interventions
Moderate-aerobic walking, Positron Emission Tomography (PET) scan, Healthy living education, Physical activity monitor
Behavioral · Radiation · Device
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 8, 2026, 7:14 AM EDT
Enrolling by invitation No phase listed Observational

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

NCT05999084
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care
Drug · Combination Product
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Albany, Georgia • Atlanta, Georgia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 8, 2026, 7:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease

NCT01560585
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Isotretinoin
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 8, 2026, 7:14 AM EDT
Not listed No phase listed Observational

Living Alone in Old Age With Cognitive Impairment

NCT03330587
View directory record Official record
Conditions
Living Alone, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 8, 2026, 7:14 AM EDT